These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37556556)

  • 1. Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens.
    Zhao J; Cochrane CS; Najeeb J; Gooden D; Sciandra C; Fan P; Lemaitre N; Newns K; Nicholas RA; Guan Z; Thaden JT; Fowler VG; Spasojevic I; Sebbane F; Toone EJ; Duncan C; Gammans R; Zhou P
    Sci Transl Med; 2023 Aug; 15(708):eadf5668. PubMed ID: 37556556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
    Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
    mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
    Zhou P; Hong J
    Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Process in the Inhibitors of UDP-3-O-(R-3-hydroxyacyl)-Nacetylglucosamine Deacetylase (LpxC) Against Gram-Negative Bacteria.
    Liu F; Ma S
    Mini Rev Med Chem; 2018; 18(4):310-323. PubMed ID: 27739357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens.
    Tomaras AP; McPherson CJ; Kuhn M; Carifa A; Mullins L; George D; Desbonnet C; Eidem TM; Montgomery JI; Brown MF; Reilly U; Miller AA; O'Donnell JP
    mBio; 2014 Sep; 5(5):e01551-14. PubMed ID: 25271285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
    Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
    Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli.
    Barb AW; McClerren AL; Snehelatha K; Reynolds CM; Zhou P; Raetz CR
    Biochemistry; 2007 Mar; 46(12):3793-802. PubMed ID: 17335290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors.
    Titecat M; Liang X; Lee CJ; Charlet A; Hocquet D; Lambert T; Pagès JM; Courcol R; Sebbane F; Toone EJ; Zhou P; Lemaitre N
    J Antimicrob Chemother; 2016 Oct; 71(10):2874-82. PubMed ID: 27330072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing zinc binding motifs.
    Jackman JE; Fierke CA; Tumey LN; Pirrung M; Uchiyama T; Tahir SH; Hindsgaul O; Raetz CR
    J Biol Chem; 2000 Apr; 275(15):11002-9. PubMed ID: 10753902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents.
    Zhang J; Zhang L; Li X; Xu W
    Curr Med Chem; 2012; 19(13):2038-50. PubMed ID: 22414079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new class of UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase (LpxC) inhibitors for the treatment of Gram-negative infections: PCT application WO 2008027466.
    Cuny GD
    Expert Opin Ther Pat; 2009 Jun; 19(6):893-9. PubMed ID: 19473108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
    Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
    Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LpxC inhibition: Potential and opportunities with carbohydrate scaffolds.
    Amudala S; Sumit ; Aidhen IS
    Carbohydr Res; 2024 Mar; 537():109057. PubMed ID: 38402732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based discovery of LpxC inhibitors.
    Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid a biosynthesis of multidrug-resistant pathogens - a novel drug target.
    Lee CR; Lee JH; Jeong BC; Lee SH
    Curr Pharm Des; 2013; 19(36):6534-50. PubMed ID: 23829374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial Drug Discovery Targeting the Lipopolysaccharide Biosynthetic Enzyme LpxC.
    Erwin AL
    Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27235477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding.
    Barb AW; Jiang L; Raetz CR; Zhou P
    Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18433-8. PubMed ID: 18025458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors.
    Liang X; Lee CJ; Zhao J; Toone EJ; Zhou P
    J Med Chem; 2013 Sep; 56(17):6954-6966. PubMed ID: 23914798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structure of LpxC from Pseudomonas aeruginosa complexed with the potent BB-78485 inhibitor.
    Mochalkin I; Knafels JD; Lightle S
    Protein Sci; 2008 Mar; 17(3):450-7. PubMed ID: 18287278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP0586532, a non-hydroxamate LpxC inhibitor, has in vitro and in vivo antibacterial activities against Enterobacteriaceae.
    Fujita K; Takata I; Yoshida I; Okumura H; Otake K; Takashima H; Sugiyama H
    J Antibiot (Tokyo); 2022 Feb; 75(2):98-107. PubMed ID: 34837061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.